Onesource doubles back on DDC contracts it had just renounced
Revenue grew 37% in Q1 but management's unexplained reversal on MSA policy clouds the $400M FY28 target.
The numbers
- Revenue hit ₹4,490 million in Q1 FY27, up 37% year-on-year, with EBITDA of ₹1,233 million rising 39%.
- EBITDA margin landed at roughly 27.5%, driven by a higher mix of drug-device combination sales.
- DDC capacity is fully utilised; the second commercial line comes online this quarter.
- Soft-gelatin fill timeline compressed to 12-15 months from roughly two years, with no disclosed catalyst.
- FY28 targets of $400 million organic revenue and 40% EBITDA margin were reiterated.
Management's story
- New master service agreements for DDC products are now a headline revenue driver.
- Semaglutide is commercialised in Canada with two additional partners launched.
- Three DDC lines will be operational by FY28; biologics RFP funnel is nearly four times the year-ago level.
- Capital expenditure of roughly $100 million is 80% committed, mostly for DDC buildout.
- Injectable site shuts in Q2 for prefilled syringe and lyophilisation upgrades; biologics development MSAs convert to commercial revenue from FY29.
“We could have continued to accept MSAs from new customers, but we decided to prioritize our capacities for commercial sales.”
— Management, Jan 2026 call
Where they diverge
In January, management said it deliberately stopped accepting new DDC MSAs to prioritise commercial sales. By July, new MSAs drove the quarter, with no explanation for the pivot. The soft-gel timeline also shortened by six to nine months without a cited demand event or utilisation disclosure. These shifts make the reiterated FY28 guidance harder to underwrite, not easier.
The full read
Onesource Specialty's Q1 numbers are strong: ₹4,490 million in revenue, up 37% year-on-year, and EBITDA of ₹1,233 million. But the quarter's real story is a strategy reversal management did not explain. In January, the company said it had stopped accepting new DDC master service agreements to keep capacity for commercial sales. By July, new MSAs were a primary growth driver. No reason was offered for the change. The same opacity surrounds the soft-gelatin timeline, shortened from roughly two years to 12-15 months with no identified demand shift or capacity utilisation figure. Management reiterated FY28 targets of $400 million revenue and 40% EBITDA margins, but without a margin bridge or clear conditions tying the two numbers together. The balance sheet looks fine with a debt-to-equity ratio of 0.13, and the DDC platform is delivering: capacity is fully booked, and a second line commercialises this quarter. Semaglutide is live in Canada. The biologics funnel is nearly four times larger than a year ago. Yet trailing PAT collapsed 95.3% in the most recent screener period, and the injectable site shuts in Q2 for upgrades. The capacity story holds. The guidance story depends on management explaining why it changed its mind.
What we're watching
- Whether DDC MSA signings sustain into Q2 and whether management discloses the utilisation rate on new soft-gel capacity.
- The injectable site shutdown in Q2 and any revenue disruption during the conversion to prefilled syringe capability.
- Biologics development MSAs converting to commercial revenue, with the first reads expected from FY29.
- Execution against the $400 million FY28 target, particularly as trailing PAT fell 95.3% in the latest screener period.